# A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

> **NCT07663838** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Randomized
- Open-label
- Safety
- Tolerability
- Pharmacokinetics
- Bacterial Vaginosis

## Interventions

- **DRUG:** GenSci142 capsule
- **DRUG:** clindamycin phosphate vaginal cream

## Key facts

- **NCT ID:** NCT07663838
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-01-05
- **Final completion:** 2027-05-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663838, "A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07663838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*